Thorsten Giesecke

Position: Health Care and Corporate Social Responsibility Advisor
Nationality / Date of Birth: German / 19th October 1967
Education:  
2007 PhD, University of Cologne, Cologne, Germany
2001-2003 Post doctorate/Fellowship, Clinical Pain Research, Georgetown University, Washington DC and University of Michigan, Ann Arbor, MI, USA
1995 Medical Doctor, University of Cologne, Cologne, Germany
Country Experience: Germany, United States, UAE
Languages: English, German
Professional Experience:  
2013-current Director, Business Unit Metabolics and Neuroscience, Janssen, Germany
2008-2013 Director, Medical Affairs, Therapeutic Areas Infectiology, Immunology, Metabolics, Neuroscience, and Oncology, Janssen, Neuss, Germany
2006-2008 Country Medical Product Lead Analgesics and Antibiotics, Janssen (Pharmaceutical branch of Johnson&Johnson), Neuss, Germany
2003-2006 Faculty and Head of Pain Clinic, University Hospital of Cologne, Cologne, Germany
2001-2003 Research Fellow, Georgetown University and University of Michigan, USA
1995-2001 Anesthesiologist, several University Hospitals, Germany

 

Mr Giesecke is responsible for a business unit of Janssen Germany with more than 30 products, annual revenue of > 200 mio €, and a team of 25 direct and non-direct reports. The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Janssen Germany commercializes the full portfolio of pharmaceutical products, services and solutions of Janssen in Germany throughout the entire life cycle.

Selected Relevant Experience:
Project Leader and Sponsor, PatCH (patient centered health care) Blue Ocean Programme, Janssen, Germany, September 2011 – January 2012
Planned, funded, managed and facilitated a Value Innovation Programme (VIP) in Germany for Janssen with 22 participants with diverse health care backgrounds (payer, physicians, health insurers, patients).  The project’s topic was Diabetes.
Participant, Deep Blue Ocean Programme, J&J, Abu Dhabi, Egypt, Tanzania, September – December 2010
Participated in a value innovation Programme in Abu Dhabi, Egypt and Tanzania sponsored by Johnson & Johnson Charitable Trust.  There were 40 participants on the programme made up of J&J executives from medical devices & diagnostics, pharmaceutical and consumer healthcare, and INSEAD MBAs.  Project topics were Tuberculosis, Diabetes, women’s health and infant mortality.
Blue Ocean Strategy Ambassador, Janssen EMEA Corporate Social Responsibility, 2010-2012
Present J&J BOS programs and outcomes in-house and externally (e.g., European Union, Brussels) to promote idea of using innovation strategy programs instead of traditional charity for CSR purposes. Set up and maintained community of BOS graduates at Janssen EMEA.
Project Manager, European Private Equity Awards, European Private Equity Association, France, 2004-2006.
Managed the European Private Equity Awards for INSEAD, 2004, 2005, 2006, which consisted of devising and implementing a strategy for sourcing, contacting and interviewing Europe’s leading private equity companies.
Summer Associate, Healthcare Venture Capital firm, LCF Rothschil, France, 2003.
LCFR is a private bank with a venture capital arm specialized in life sciences. Responsible for analysing investment status of portfolio companies and assessing new investment opportunities in the US; reported to the Senior Manager. Due diligence leader regarding CNS focused companies. Active in company’s strategy meetings regarding raising a new fund (€150MM).
Senior Analyst, Healthcare Venture Capital firm, Domain Associates, Princeton, NJ, USA, 1999-2002.
Domain Associates is a $1.2 billion venture capital firm focusing on life sciences. Launched and managed company-wide deal flow and entrepreneur relations system resulting in a 70% time management improvement. Performed due diligence on early-stage healthcare companies; investment range was between $7M and $12M. Structured and negotiated term sheets for investments.  Evaluated business plans, interviewed management teams, interacted with CEOs, investment bankers and founders regarding their business models.